Skip to main content
Premium Trial:

Request an Annual Quote

Acacia's Patent-Acquisition Subsidiary Licenses Nucleic Acid-Purification IP

This article corrects an earlier version that mistakenly reported that Acacia Technologies subsidiary CombiMatrix licensed the IP.
NEW YORK (GenomeWeb News) — Acacia Research Corporation last week said that Acacia Patent Acquisition Corporation, a wholly owned subsidiary of Acacia Technologies, has acquired rights to patents relating to purifying nucleic acids.
Acacia did not disclose the name of the entity that sold it the IP, but said that the patents “generally relate to methods and equipment used to purify plasmid DNA products.”
The company said the technology could be used to produce "ultrapure pharmaceutical quality nucleic acids for DNA-vaccines and gene therapies” for a variety of diseases.
Financial terms of the agreement were not released.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.